Comparative Study with CHOP-Pepleo and COP-Pepleo Combunation Chemotherapy for Non-Hodgkin's Lymphoma

Comparative Study with CHOP-Pepleo and COP-Pepleo Combunation Chemotherapy for Non-Hodgkin's Lymphoma

Creators Tanaka Masahisa

Creators Azuno Yoichi

Creators Yoshizaki Yoshiki

Creators Hatao Katsuhiro

Creators Fujii Yasuhiko

Creators Okubo Masashi

Creators Inoue Yasushi

Creators Matsutani Akira

Creators Yaga Ken

Creators Fujii Shinya

Creators Ishida Yoji

Creators Kaku Kohei

Creators Matsumura Shigeichi

Creators Kaneko Toshio

Creators Shinohara Kenji

Creators Hiroshige Yukio

Creators Matsumoto Noboru

Combination chemotherapy with CHOP-Pepleo regimen (cyclophosphamide, adriamycin, vincristine, prednisolone, and pepleomycin), or COP-Pepleo refimen (cyclophosphamide, vincristine, prednisolone, and pepleomycin), was used as a remission induction therapy for patients with mostly advanced non-Hodgkin's lymphomas. Among 23 patients treated with CHOP-Pepleo or CHOP without Pepleo (5 patients), 57% achieved complete remission with 78% overall response (complete remission plus partisl remission). Among 12 patients treated with COP-Pepleo, 50% achieved complete remissions with 83% overall response. No significant difference was odserved in response rates between two groups. Median follow-up durations ware 14 months for CHOP-People and 16 months for COP-Pepleo and 4 patients (67%) treated with COP-Pepleo relapsed within 20 months after achieving complete remission. Relapse-free survival rates at 4 years ware 54% for CHOP-Pepleo and 34% for COP-Pepleo. Each survival curve in the patients treated with CHOP-Pepleo or COP-Pepleo showed a plateau after 24 months. Though the addition of adriamycin did not improve complete remission rate significantly as a whole, the complete remission rate in stage Ⅳ , overall survival and relapse-free survival ware favorably inproved by the addition of adriamycin. Further study will be needed to assess the effect of adriamycin on response and survival in patients eith non-Hodgkin's lymphomas.

[ISSN]0513-1812

[NCID]AA00594272